CHANGES IN ANTIBODIES TO C1Q PREDICT RENAL RELAPSES IN SYSTEMIC LUPUS-ERYTHEMATOSUS

The presence of elevated plasma levels of autoantibodies against Clq, a subcomponent of the first component of complement in sera of patient s with systemic lupus erythematosus (SLE) has been found to be associa ted with renal involvement, The purpose of this study was to determine whether increases in anti-Clq antibodies (anti-C1q) precede renal inv olvement in SLE, Forty-three SLE patients were studied longitudinally to determine the relationship between manifestations of the disease an d levels of anti-Clq as well as to identify antibodies against double- stranded DNA (anti-dsDNA). Increased levels of anti-Clq were detected in all 14 of the patients who developed proliferative lupus nephritis out of 17 patients with renal relapses, which was significantly more f requent (P < 0.005) than in patients with nonrenal relapses (six of 16 patients) or with inactive disease (two of 10 patients). Increased an ti-dsDNA levels were observed in 14 of 17 patients with renal relapses compared with 15 of 16 patients with nonrenal relapses and five of 10 patients with inactive disease, Significant increases in anti-Clq lev els prior to the relapse occurred in 10 of 14 patients who developed p roliferative nephritis and in three of 16 patients with nonrenal relap ses, Significant increases in anti-dsDNA levels occurred in 11 patient s of the former group and in nine patients of the latter group, No sig nificant increases in anti-Clq or anti-dsDNA levels were observed in t he patients with inactive disease, The mean time period between the oc currence of a significant increase in anti-Clq or anti-dsDNA level and the moment of renal relapse for both antibodies was 2.3 months, These results suggest that an increase in anti-Clq level has a predictive v alue for an ensuing renal relapse of proliferative lupus nephritis, an d that serial measurements of anti-Clq levels might be useful in the m anagement of SLE patients. (C) 1995 by the National Kidney Foundation, Inc.